Trial Profile
Effectiveness, safety and survival rate in patients with Rheumatoid Arthritis after 12 months of treatment with Certolizumab PEGol among Spanish population in clinical practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2018 New trial record
- 16 Jun 2018 Results (n=501) presented at the 19th Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Results (n=360) presented at the 19th Annual Congress of the European League Against Rheumatism